Sustained-release bupropion smoking cessation in African Americans - A randomized controlled trial
Sustained-release bupropion smoking cessation in African Americans - A randomized controlled trial
复制标题
DOI：
10.1001/jama.288.4.468
复制
发表时间：
2002-07-24
影响因子：
120.7
通讯作者：
Mayo, MS
中科院分区：
文献类型：
--
作者：
Ahluwalia, JS;Harris, KJ;Mayo, MS
背景非裔美国人不成比例地经历更大的吸烟归因的发病率和死亡率。尽管非裔美国人的吸烟和戒烟模式各不相同，但很少有针对非裔美国人的戒烟临床试验。目的比较盐酸安非他酮缓释片的缓释效果（安非他酮SR）与安慰剂用于非裔美国人的戒烟。设计、设置和参与者从1999年2月11日至12月8日进行的随机、双盲、安慰剂对照试验。2000年，600名非洲裔美国成年人在社区卫生保健中心接受治疗。每天吸烟10支或以上的志愿者由目标媒体和卫生保健专业人员招募。干预参与者被随机分配接受150 mg安非他酮SR（n=300）或安慰剂（n=300），每天两次，持续7周。在基线、戒烟日、第1周和第3周、治疗结束时（第6周），以及第3天、第5周和第7周通过电话提供简短的动机咨询。主要结果测量在戒烟日后的第6周和第26周，生化证实的7天点戒烟率。治疗7周结束时，安非他酮缓释剂组和安慰剂组的确认戒烟率分别为36.0%和19.0%（17.0个百分点的差异; 95%置信区间，9.7-24.4; P
Context African Americans disproportionately experience greater smoking attributable morbidity and mortality. Few clinical trials for smoking cessation in African Americans have been conducted, despite a different profile of both smoking and quitting patterns.Objective To compare a sustained-release form of bupropion hydrochloride (bupropion SR) with placebo for smoking cessation among African Americans.Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial conducted from February 11, 1999, to December 8, 2000, of 600 African American adults treated at a community-based health care center. Volunteers, who smoked 10 or more cigarettes per day were recruited by targeted media and health care professionals.Intervention Participants were randomly assigned to receive 150 mg of bupropion SR (n=300) or placebo (n=300) twice daily for 7 weeks. Brief motivational counseling was provided in-person at baseline, quit day, weeks I and 3, end of treatment (week 6), and by telephone at day 3 and weeks 5 and 7.Main Outcome Measures Biochemically confirmed 7-day point prevalence abstinence at weeks 6 and 26 following quit day.Results Using intention-to-treat procedures, confirmed abstinence rates at the end of 7 weeks of treatment were 36.0% in the bupropion SR group and 19.0% in the placebo group (17.0 percentage point difference; 95% confidence interval, 9.7-24.4; P